Over the last three months, we've seen significantly more insider buying, than insider selling, at Bristol-Myers Squibb.
We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...
Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...
Bristol Myers Squibb (BMY) says its cancer drugs Opdivo and Yervoy improved progression-free survival in a Phase 3 trial for ...
Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...
1d
Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...
Bristol-Myers Squibb’s $2.6B pension risk transfer lawsuit is ‘frivolous,’ say industry groups
The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...
This was the stock's third consecutive day of gains.
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback